Danshen is a traditional Chinese root herb used for blood circulation, heart and kidney health, and male urinary function. For standalone oral extracts, human evidence reaches a medium level only for relieving male urinary symptoms and supporting erectile function. Heart, kidney, and stroke claims rest on low or conflicted evidence, while oral use can raise harmful cholesterol, speed up prescription medication breakdown, and cause severe bleeding with warfarin. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting LDL Cholesterol | < 2.6 mmol/L (< 100 mg/dL; cessation threshold: rise ≥ 0.30 mmol/L) | Safety check and conflicted efficacy marker: oral aqueous Danshen raised LDL by 0.30 mmol/L in hyperlipidemic adults |
| Seated or 24-Hour Ambulatory Blood Pressure | < 130/80 mmHg (standard < 120/80 mmHg) | Expected efficacy marker: tracks vascular response in mild-to-moderate hypertension |
| eGFR and Serum Creatinine | ≥ 90 mL/min/1.73 m² (paired with spot urine albumin-to-creatinine ratio) | Expected efficacy and safety marker: tracks renal filtration preservation in kidney disease |
| Platelet Count (via CBC) and PT/INR | Platelets 150–450 × 10⁹/L; INR 0.8–1.2 | Safety check: detects rare reversible thrombocytopenia or coagulopathy (cessation threshold: platelets < 150 × 10⁹/L) |
| IPSS and IIEF Questionnaires | Reduction in IPSS and increase in IIEF from individual baseline (no established target) | Expected efficacy marker: quantifies LUTS relief and erectile function in men |
Cadence: Baseline testing before initiation; re-evaluate blood pressure and qualitative tolerance at 2 to 4 weeks (and IPSS/IIEF at 4 weeks); repeat fasting LDL cholesterol, CBC, and renal panels at 4 to 8 weeks; assess full clinical efficacy at 12 weeks; repeat labs every 6 months during cyclical use.